Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 26-May 2015. Module: Canada Health Infoway English module (core metadata concept)
Descriptions:
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | Count of base of active ingredient | un | false | Inferred relationship | Some | ||
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | a pour principe actif (attribut) | Haemophilus influenzae type b capsular polysaccharide polyribosylribitol phosphate antigen conjugated to Clostridium tetani toxoid protein | true | Inferred relationship | Some | 1 | |
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | est un(e) (attribut) | Haemophilus influenzae type b capsular polysaccharide antigen conjugated only vaccine product | false | Inferred relationship | Some | ||
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | Has supplier | GlaxoSmithKline Inc. (supplier) | true | Inferred relationship | Some | ||
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | Plays role | Active immunity stimulant role (role) | true | Inferred relationship | Some | ||
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | est un(e) (attribut) | Product manufactured as parenteral dose form (product) | true | Inferred relationship | Some | ||
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | a une forme pharmaceutique (attribut) | forme pharmaceutique pour usage parentéral (forme pharmaceutique) | true | Inferred relationship | Some | ||
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | est un(e) (attribut) | Vaccine product containing only Haemophilus influenzae type b capsular polysaccharide polyribosylribitol phosphate conjugated to Clostridium tetani toxoid protein (medicinal product) | true | Inferred relationship | Some | ||
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | est un(e) (attribut) | Haemophilus influenzae Type b vaccine | false | Inferred relationship | Some | ||
| Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug) | a pour principe actif (attribut) | Haemophilus influenzae type b vaccine (substance) | false | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Administered tradename codes for vaccines reference set (foundation metadata concept)
FHIR